Entera Bio Ltd. - ADR (ENTX)

Name: Entera Bio Ltd. - ADR (ENTX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Entera Bio Ltd. - ADR (ENTX)

Stock Card

$3.03

$-0.05 (-1.62%)

As on 28-Aug-2026 16:00EDT

Market cap

$525 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

72.9

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Entera Bio - ADR (ENTX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 3.00 High: 3.15

52 Week Range

Low: 0.91 High: 4.20

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.5
Debt to Equity

0
Book Value

$0.1
EPS

$-0.4
Face value

--
Shares outstanding

173,141,831

9 Years Aggregate

CFO

$-69.17 Mln

EBITDA

$-87.38 Mln

Net Profit

$-81.99 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Entera Bio - ADR (ENTX)	56.2	-22.7	154.6	54.6	64.1	-8.9	--
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5

As on 28-Aug-2026 | *As on 31-Aug-2026

Company	2025	2023	2022	2021	2020	2019
Entera Bio - ADR (ENTX)	-8.5	-17.8	-74.1	160.6	-49.5	-29.8
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Entera Bio - ADR (ENTX)

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the... treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel. Read more

CEO & Director

Ms. Miranda J. Toledano M.B.A.
CEO & Director

Ms. Miranda J. Toledano M.B.A.
Headquarters

Jerusalem
Website

https://enterabio.com

FAQs for Entera Bio - ADR (ENTX)

What is the current share price of Entera Bio Ltd - ADR (ENTX) Today?

The share price of Entera Bio Ltd - ADR (ENTX) is $3.03 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Entera Bio Ltd - ADR (ENTX) has given a return of 64.07% in the last 3 years.

What is the current PB & PE ratio of Entera Bio Ltd - ADR (ENTX)?

Since, TTM earnings of Entera Bio Ltd - ADR (ENTX) is negative, P/E ratio is not available.
The P/B ratio of Entera Bio Ltd - ADR (ENTX) is 72.92 times as on 28-Aug-2026, a 1376 premium to its peers’ median range of 4.94 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-7.83	6.84
2024	-8.37	9.88
2023	-2.01	1.72
2022	-1.61	1.79
2021	-6.62	3.58

What is the 52 Week High and Low of Entera Bio Ltd - ADR (ENTX)?

The 52-week high and low of Entera Bio Ltd - ADR (ENTX) are Rs 4.20 and Rs 0.91 as of 31-Aug-2026.

What is the market cap of Entera Bio Ltd - ADR (ENTX)?

Entera Bio Ltd - ADR (ENTX) has a market capitalisation of $ 525 Mln as on 28-Aug-2026. As per SEBI classification, it is a company.

Should I invest in Entera Bio Ltd - ADR (ENTX)?

Before investing in Entera Bio Ltd - ADR (ENTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.